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Background: Approximately 20% of children live with a chronic physical condition, such as 
asthma, epilepsy, or diabetes. These conditions place considerable burden on children, their 
families, clinicians, and the health system. However, these burdens are reduced when conditions 
are effectively managed, typically accomplished by appropriately monitoring the severity and 
progression of the condition. Several condition-specific scales exist for measuring severity in 
children but are limited in their clinical utility for general practitioners or pediatricians who care 
for children with different conditions. 
 
Objectives: This study aimed to validate the Global Assessment of Severity of Illness (GASI)—
a single-item scale that can be used to measure severity in children with different chronic 
physical conditions. Study objectives were to examine the construct validity, test-retest 
reliability, responsiveness, and sensitivity/specificity of the GASI. 
 
Methods: Clinicians assessed severity of asthma, food allergy, epilepsy, diabetes, and juvenile 
arthritis in 56 children using the GASI, Duke Severity of Illness Scale (DUSOI; the external 
clinical anchor), and a general visual analogue scale (VAS). Parents reported on child health-
related quality of life using the KIDSCREEN-27. Kendall’s Tau-c and area under the receiver 
operating characteristic curve (AUC) determined the strength of association between measures. 
Fisher’s Exact test indicated whether the GASI could discriminate between children with and 
without multimorbidity. McNemar’s test, the Kappa coefficient, and weighted Kappa assessed 
stability in GASI ratings over time. The standardized response mean and Guyatt’s 
responsiveness index examined internal and external responsiveness, respectively. AUC 
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determined sensitivity/specificity. Clinician characteristics, as potential confounders, were 
investigated within AUC regression models. 
 
Results: The GASI demonstrated strong correlations with the DUSOI composite score (tc= 0.57-
0.63; AUC= 0.83-0.96) and VAS (tc= 0.78) and weak correlation with health-related quality of 
life (tc < 0.1). Lack of discrimination between children with and without multimorbidity was 
indicated by Fisher’s Exact test (p-value > 0.05). Moderate to substantial test-retest reliability 
was supported by McNemar’s test (p-value > 0.05), Kappa (k= 0.79; CI= 0.51-1.00), and 
weighted Kappa (kw= 0.57; CI= 0.36-0.78). The GASI was largely responsive (Cohen’s d= 0.84; 
CI= 0.68-1.11) and the magnitude of sensitivity/specificity was low to moderate (AUC= 0.62-
0.81). Construct validity was excellent regardless of whether regression modeling accounted for 
type of diagnosis, clinician, or child age. 
 
Conclusion: Initial evidence supports validity of the GASI to make meaningful comparisons of 
severity between different chronic conditions in children. Future research using larger samples 
should aim to replicate these findings and test inter-rater reliability between different health 
professionals. Such work is needed to fill knowledge gaps in comparative pediatric research and, 
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Introduction and Overview 
Approximately 20% of children live with a chronic physical condition, such as asthma, 
epilepsy, or diabetes.1 These conditions place considerable burden on children, their families, 
and clinicians. At a systems level, chronic conditions account for 42% of health care costs 
among children.2 Moreover, children with chronic conditions are at increased risk for mental 
disorder and their families experience more stress and financial hardship than those of their 
healthy peers.3 However, these burdens are reduced when conditions are effectively managed, 
typically accomplished by appropriately monitoring the severity and progression of the 
condition.4–8 
Monitoring severity often involves assessment using a health measurement scale, a 
number of which have been developed that accurately and reliably measure condition severity. 
These scales are developed in various forms, with some using multiple items to represent the 
latent construct of severity, and others using only a single item. The latter method is based 
primarily upon global judgment of the rater, and can improve upon limitations of the former. 
Several condition-specific severity scales for children exist but are limited in their clinical 
utility for general practitioners or pediatricians who care for children with different conditions. 
Clinical utility can be improved with a quick and easy to use scale that can be used across 
conditions. Reasons why clinicians forego routine measurement include lack time and lack of 
scale versatility.9 From a research standpoint, a scale that could be used across conditions would 
also be useful for making group-based comparisons. 
Adapted from the Global Assessment of Severity of Epilepsy (GASE),10,11 the Global 
Assessment of Severity of Illness (GASI) is a single-item scale that can be used to measure 
severity in children with different chronic physical conditions. This study investigates the 
validity, reliability, responsiveness and sensitivity/specificity of the GASI. Because the GASI 
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requires little time of clinicians and addresses various complications in measuring severity of 
different conditions, it has potential to improve measurement, and possibly, management of 
chronic conditions in children. 
This thesis begins with a review of research and health care concerning children with 
chronic conditions, including the management of these conditions with the help of severity rating 
scales. I then explain the rationale behind development and validation of the GASI, and how it 
improves upon the limitations of current severity scales. Afterward, I describe how clinical data 
was collected using the GASI and the statistical methods used to assess its psychometric 
properties. I present the results from psychometric testing and discuss the implications of these 
findings for research and clinical practice. Finally, I end by reviewing the strengths and 
weaknesses of this study in addition to proposing important directions for future research. 
 3 
Literature Review 
Children with Chronic Physical Conditions 
 In children, chronic physical conditions are prevalent, burdensome, and difficult to 
manage. A chronic physical condition (CPC) is a disorder that has a biologic basis, will last at 
least one year, and produces at least one of the following sequelae: (a) limitation of physical 
function in comparison with healthy peers; (b) dependency on medications, special diet, medical 
technology, assistive devices, or personal assistance; or (c) need for ongoing medical 
care/accommodation. This modified definition12 excludes mental disorders1,13 to clarify the 
unique factors associated with CPCs in children. 
The most common CPCs in children are asthma, food allergy, epilepsy, diabetes and 
hypertension.14 The burdens associated with these conditions include those mentioned in the 
above definition and also include comorbidity. In a large Canadian population-based cohort, 
Ferro et al.3 found that children with CPCs are at risk for increased symptoms of anxiety and 
depression, which corroborates evidence from a large longitudinal study in British children.15 
Pinquart et al.16 conducted a meta-analysis and found that children with CPCs had elevated 
levels of anxiety and depression compared to those without CPCs. In addition to outcomes of 
psychopathology, Varni et al.17 investigated child and parent reports and found that children with 
CPCs experienced worse health-related quality of life (HRQL) than healthy children. Burdens of 
childhood CPCs extend to parents and siblings and include distress surrounding the child’s 
health and safety,18–20 anxiety related to caregiving responsibilities21,22 (e.g., building 
relationships with clinicians),23 increased levels of interpersonal stress,24 and financial burden25 
compared to families of children without chronic conditions. The burden of mortality is great, 
with CPCs being among the top five leading causes of childhood deaths.26 Many of the burdens 
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experienced by children with CPCs are moderated by condition specific factors, including 
severity,16,17,27,28 making severity measurement an important component of managing CPCs. 
Prevention and Management of Chronic Conditions 
Measurement of patient outcomes is essential to the work of many health professionals 
and researchers. In the clinical setting, children with CPCs are typically diagnosed and treated on 
the basis of outcomes including biologic markers, symptoms experienced, and responses to 
intervention.29 Often with the use of scales, this information is obtained by clinicians,30–32 
caregivers7,8 and patient proxies,33–35 and patients themselves.36  Routinely monitoring these 
outcomes over time is essential for tailoring individual stepped care29 for people with chronic 
conditions and is crucial to the success of the Chronic Care Model in children37 and adults.38 
In the past few decades, the call for outcome measurement in children8,9,37,39 and 
adults40,41 with chronic conditions has been primarily limited to physiologic monitoring of select 
conditions42 such as diabetes43 and cancer.30 Although physiologic measurement is often 
necessary with these conditions, it may not be sufficient for tracking overall patient progress. For 
example, an individual with cancer may provide a blood sample indicating a reduction in cancer 
cells, but such a measure will not examine whether functional capacity of the individual has 
improved. Dimensions of health such as functional capacity, pain, or condition severity must be 
subjectively measured and such measurements are crucial to monitoring chronic conditions. 
Kelley et al.39 refers to measurement of multiple health dimensions as multidimensional 
measurement or monitoring, a practice which is increasingly emphasized in general medical 
practice,44–46 including care for children with CPCs.47 Bickman et al.48 also found that many 
clinicians value receiving regular multidimensional reports on the progress of their patients. 
There is evidence that routine outcome monitoring using multidimensional measurement can 
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predict deterioration in the health of patients9 and improve treatment outcomes41,49 when 
implemented appropriately.50 
In clinical research, the measurement of patient outcomes has also been useful for 
improving understanding of chronic conditions in children. Cross-sectional investigation, for 
instance, has been important for studies examining HRQL outcomes in children with CPCs.28 
Likewise, longitudinal research has been used to investigate questions such as whether 
depressive symptoms in parent-proxies affect their reports on health outcomes in their child with 
epilepsy.51 Outcome measurement also plays an important role in public health research. Disease 
surveillance52,53 uses routine outcome monitoring data to enhance program planning, 
accountability, and disbursement of funding for the prevention of chronic conditions.54 
Health Measurement Scales 
The type of outcome that can be obtained from a health measurement scale is determined 
by how the scale was developed. Initial development of a health measurement scale involves 
quantifying estimates of healthiness by assigning numerical scores or ordinal categories to 
subjective clinical judgments.55 When objective measurement of a health outcome (e.g., severity) 
is not possible, a subjective process is required. Subjective assessment of health by use of a scale 
has shown to be valid and reliable.55 To assess a health construct that is non-observable (i.e., a 
latent construct), many scales use multiple items or questions to measure observable variables 
that are related to the latent health construct. Ideally, combining measurements of these variables 
will provide a more accurate assessment of the latent construct versus assessing the latent 
construct directly.56 Using a multi-item scale also provides information about how different 
items specifically contribute to the measurement of a latent construct. However, single-item 
scales have been considered to be better measures of latent constructs in a number of 
situations.55,57 
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Completion of a single-item scale relies on the informant’s expertise of the measured 
construct because additional items are not provided to guide judgment. When multi-item scales 
measure complex constructs, there is the possibility that relevant elements of the construct are 
neglected. With a single-item scale, the informant is not limited by specific items but is free to 
consider all elements relevant to the latent construct. There is evidence that clinicians can 
adequately estimate latent constructs in this way.58 Centrally reliant on clinician judgment, 
single-item scales often perform similarly to multi-item scales,55 and can outperform multi-item 
scales when measuring certain constructs.57 Most importantly, single-item scales have been 
shown to demonstrate many forms of validity and reliability.55 
The most common forms of single-item scales include the visual analogue scale (VAS), 
Likert, and numeric rating scale. The rating format of the Likert and numeric rating scale are 
considered ordinal, as opposed to continuous, because the response options are separated into 
distinct ordinal categories.59,60 The VAS is a continuous line, often 100 mm in length, anchored 
by descriptions indicating minimum and maximum endpoints of the scale between which the 
rater places a mark. Some argue that the VAS is not truly continuous because raters still place 
their mark as if the scale were composed of different categories,61 while other studies report that 
this only occurs in VASs with intermittent numbers or symbols.62 With no categories to guide 
comparison of different ratings on the VAS, interpretation of meaningful change risks bias.63 
Traditionally, each response option on a Likert scale is anchored by adjectives or descriptive 
phrases, while numeric rating scale categories are labeled by numbers and anchored with 
descriptions at the minimum and maximum ends of the scale.61 Some single-item scales are 
graphical, such as The Faces Scale,55 and represent a construct such as mood or pain along a 
continuum of different facial expressions. The graphical scale is often useful with young children 
and in cases where language barrier prevents patients from being able to read scale 
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descriptions.64 Each single-item scale format has advantages and disadvantages, but all have 
been found useful in clinical practice and research.59 
The Feasibility and Utility of Scales for Measuring Patient Outcomes 
 Implementation of routine multidimensional measurement in clinical practice has proven 
difficult.9,31,50,65–70 Because scales contribute to this measurement, identifying issues of scale 
feasibility and utility may help improve scale development and the success of measurement 
implementation. The following three issues are commonly found among health measurement 
scales: 1) The time required for completion is often not practical for busy clinics;9 2) Scales have 
not been validated for measurement across different conditions;71,72 and 3) Information obtained 
from scales are typically useful for the clinician, and rarely to additional stakeholders, such as 
administrators.9 
Issue 1: The time required to complete a scale primarily depends on the length and 
complexity of the scale. Clinicians are rightly concerned about giving up current rhythms of 
practice to adopt those which will accost time from their schedule. Already clinicians do not 
have enough time to meet practice guidelines for chronic care.73 In the U.S., some insurance 
reimbursement policies have led clinicians to limit visits to ten minutes.74 In consideration of 
time constraints, scales that require less time from clinicians are better for maintaining desired 
workflow. Ideal incentivization of multidimensional monitoring will rely on factors other than 
money. In the U.S., most clinicians are not financially reimbursed for multidimensional 
monitoring, while they are often reimbursed for running physiological tests.9 Although Canada 
has implemented financial incentives for physicians requiring additional time for clinical 
assessments, such incentives may not be sustainable.75 Alternative incentives include quick and 
simple initiatives that improve patient outcomes. 
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 Evidence suggests that implementation of clinical activities, such as outcome 
documentation,76,77 is more successful when less time is required from individuals involved.68,78 
Moreover, clinical initiatives are more likely to have long-term success when they are easy to 
understand.79 While many scales are being developed with fewer items and shorter length,55,80 it 
is important to remember how these characteristics affect the utility and psychometric integrity 
of the scale. If clinicians are to consider the utility of scales that are short and simple, scale 
developers must ensure that such scales retain the validity and reliability integral to their use. 
 Issue 2: Development of scales that can be used for multiple conditions should be 
considered for the following reasons: 1) Determining eligibility of a scale for multiple patients 
with different conditions can be an overwhelming process,67 and so the availability of condition-
generic scales can reduce the number of scales that clinicians need to review; 2) Multimorbidity 
assessment is simplified by using one scale across conditions;81 and 3) Standardized 
measurement is needed for valid cross-condition comparison.82 
 Issue 3: Implementation of an activity will typically be more successful when it benefits 
multiple stakeholders in a system.78 Scale developers should be cognizant of this principle when 
designing scales to be implemented for routine measurement. For example, in addition to 
clinicians, administrators and payers are also stakeholders in routine measurement because they 
need access to actionable information9 to predict healthcare utilization and assess overall quality 
of care.70,83 Because severity scales provide useful information for these objectives,84–86 efforts 
should be made to improve the quality and utility of such scales. 
Measuring Severity 
 Severity scales have been developed for different purposes. When the purpose is not 
explicit, a scale might be used to measure constructs other than which it was intended. In the 
words of Ruth Stein, “an appropriate method [of measurement] cannot be selected without 
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knowledge of purpose.”87 For example, it is unclear whether many asthma scales are assessing 
asthma severity or asthma control, an important distinction within this condition, especially 
among children.88 Evidently, the definitions of severity are as diverse as the purposes for 
measuring severity. A popular understanding of the different types of severity considers three 
categories: “physiological or morphological severity; functional severity; and burden of 
illness.”87 When a scale is designed to predict organ failure89 or mortality,90 it is essentially 
designed to measure and predict “physiological/morphological” severity. When the goal is to 
measure global severity, the scale should measure all three categories in a weighted or 
unweighted manner. 
 Severity scales exist in multi- and single-item form and most often use patient-based (i.e., 
specific to the patient) rather than condition-based metrics (i.e., specific to the condition).91 The 
majority of patient-based scales have been developed to measure severity in a specific 
condition10,92–97 or a specific subset of conditions.76,98,99 Scales limited to the measurement of 
specific conditions can be referred to as categorical scales, while non-categorical scales allow the 
measurement of virtually any condition.12  
While non-categorical multi-item scales are useful for prompting the consideration of 
various aspects of condition severity, important aspects are often neglected.57,100 This problem is 
sometimes ameliorated by limiting the scale to a single item.56,101 Unfortunately, literature 
surrounding single-item scales is sparse, and include a number of reports where clinicians used 
single-item severity scales that were not validated.93,102 In three different studies on arthritis, 
including juvenile arthritis, clinicians used the same single-item scale that had no evidence for 
validity.103–105 Such scales can potentially misinform research because there is no evidence that 
they are measuring what they purport to measure, the severity of arthritis. These cases speak to 
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the need for further development and validation of single-item scales that measure condition 
severity. 
Severity Scales for Chronic Physical Conditions in Children 
Despite the rapidly growing evidence-base for the validity and reliability of brief 
scales,80,106 only two scales are relevant for clinician global assessment of severity in children 
with different CPCs: The Severity of Illness Index and The Duke Severity of Illness Scale. 
The Severity of Illness Index (SII): The SII was initially developed as a non-categorical 
generic severity scale for hospital inpatients.107 While the SII has undergone a series of 
alterations to improve its measurement specificity and validity in children, the original and 
alternative versions continue to be commonly used. The original SII is a seven-item scale with 
items measuring stage of principal diagnosis, complications, interactions, dependency, 
procedures, response to therapy, and remission of symptoms, and requires 2 to 15 minutes to 
complete.107 Response options range from 1 to 4 with each option labeled by severity criteria 
specific to the item.107 Most SII validation studies have not specified age, but at least one is 
known to include children.108 The SII has demonstrated excellent interrater agreement (90.8%-
97.7%), good face validity as agreed between clinicians, and predictive validity with regard to 
resource use.109 Interrater reliability of the SII varies with the type of health professional rating 
the condition (weighted Kappa= 0.69-0.79).107 The SII is less reliable in individuals with 
moderate condition severity versus extreme severity.108 
An updated, seven-item version of the SII is known as the Comprehensive/Computerized 
Severity Index (CSI).110 Though still a non-categorical scale, condition-specific descriptions are 
provided when a diagnosis is specified. Condition descriptions are enabled by computer 
algorithms built in the CSI. Because of its success in adults,110–112 a version of the CSI was 
developed specifically for use in children. The Pediatric CSI85 has been shown to predict and 
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discriminate mortality (Hosmer-Lemeshow tests: p-value= 0.41-0.98; AUC= 0.89-0.99, p-value 
< 0.001) and explain variation in length of stay and cost of services (R2 = 0.13-0.67; R2 = 0.08-
0.73, p-value < 0.005).85 
The Duke Severity of Illness Scale (DUSOI): The DUSOI measures severity of various 
conditions, using four items that assess symptoms, complications, prognosis, and treatability.113 
Each item is a five-point numeric rating scale. While a composite score of these four items 
provides a global assessment of condition severity, the DUSOI also includes a single-item global 
assessment in the form of a horizontal VAS.113 Using the DUSOI composite score, five studies 
provided evidence for interrater reliability (ICC= 0.45-0.79)86,113–116 and two demonstrated intra-
rater reliability for individuals with CPCs (ICC= 0.67-0.89).114,116 There is also evidence for 
agreement between the DUSOI composite score and the VAS (ICC= 0.61, p-value < 0.001).113 
Although little effort has been made to assess concurrent validity of the DUSOI, the scale shows 
good clinical face validity116 and has demonstrated predictive validity in its ability to predict 
future health service charges (R2= 0.05).86 Only a subset of DUSOI validation studies included 
samples with infants, children, or adolescsents.115,116 Although the DUSOI takes only one to two 
minutes to complete,115,116 complexity of administering the DUSOI makes it less feasible than 
alternative severity scales.81 For example, in a study where thirty clinicians used the DUSOI to 
assess severity, nearly 30% of clinicians reported having difficulty using the scale.116 
Although these scales present a number of benefits to measuring severity of CPCs, the 
needs of many clinicians and researchers remain unmet. In sum, the SII is currently limited by its 
response time (up to 15 minutes), scant evidence for valid use in children, and inability to 
measure outpatients and individuals with moderate condition severity. However, revisions of the 
SII resulted in some improvements: The computerized version has been shown to take only 2 
minutes to complete, and the Pediatric CSI has demonstrated valid use among a large sample of 
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hospitalized children. Development of an outpatient version of the Pediatric CSI has been 
reported,85 but has not been validated. 
Limitations of the DUSOI include complexity of use, average response times ranging 
over one minute, and clinicians reporting its lack of utility for child health examination.115 
Moreover, clinicians participating in the current study have reported that items on the DUSOI 
complicated assessment of severity. The VAS that was specifically validated for use with the 
DUSOI may ameliorate such time and complexity issues. However, the DUSOI VAS has not 
been validated in a child sample and VASs have, at times, been considered impractical for the 





The Gap in Child Severity Measurement 
In response to the limitations of current scales, I performed initial validation of the 
Global Assessment of Severity of Illness (GASI), a scale specifically developed for the needs of 
researchers and clinicians caring for children with various CPCs. The GASI is a single-item scale 
that allows for quick and simple global assessment of severity. As a single-item Likert-type 
scale, the GASI is expected to improve upon the limitations of similar severity scales (e.g., 
SII/Pediatric CSI, DUSOI), and provide a step toward standardized measurement of severity 
across children with different chronic conditions. 
Study Objectives 
 Validation of the GASI included the following tests: 1) Construct validity: whether the 
scale measures what it purports to measure—the overall severity of a condition; 2) Test-retest 
reliability: whether the scale returns similar severity measurements at different points in time in 
the subgroup of children whose condition did not change according to an established clinical 
measure; 3) Responsiveness: whether the scale is able to detect clinically important changes in 
the severity; and 4) Sensitivity/Specificity: the probability that the GASI will correctly measure 
change and no change on an external criterion.117 
Hypotheses 
 To achieve these objectives the following hypotheses were tested sequentially according 
to convention in scale validation research:55 
1. Construct validity: 
a. Concurrent validity: The GASI will have at least moderate correlation (tc ≥ 
0.3),118 and demonstrate strong relationships (AUC ≥ 0.7),119 with two established 
measures of global severity, the VAS and the DUSOI. 
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b. Discriminant validity: The GASI will be moderately correlated (tc > 0.30) with 
HRQL domains on the KIDSCREEN-27 that represent the severity construct, and 
correlate weakly (tc= 0.10-0.30) with HRQL domains that do not represent 
condition severity. Additionally, because the GASI is a global assessment, its 
relationships with the VAS and the DUSOI composite score will be stronger than 
with individual items on the DUSOI.120 
c. Discriminative validity: GASI ratings will be higher for children with 
multimorbidity (comorbid mental disorder) versus children without 
multimorbidity (p-value < 0.05). 
2. Test-retest reliability: GASI ratings will not change from baseline to six months in stable 
subgroups (p-value > 0.05) and will demonstrate adequate test-retest reliability (k ≥ 0.7). 
3. Responsiveness: The GASI will demonstrate a moderate to large magnitude of 
responsiveness (Cohen’s d > 0.5) in both a distribution-based assessment (no clinical 
anchor) and an anchor-based assessment. 
4. Sensitivity/Specificity: The GASI will demonstrate at least moderate 
sensitivity/specificity (AUC ≥ 0.7)119 with the DUSOI composite score as an external 




 Data come from the Researching Adolescent and Child Health study (REACH), a six-
month prospective pilot study that aimed to assess mental disorders in children newly diagnosed 
with a CPC.121 In addition to appraising the feasibility of a larger follow-up study, goals of the 
REACH pilot study were to assess the prevalence of child multimorbidity, identify factors 
correlated with multimorbidity in children and parents, and assess the effects of multimorbidity 
on changes in child quality of life and parental psychosocial outcomes over six months. Health 
professionals recruited families from two pediatric academic hospitals in Ontario, Canada with 
the aim of recruiting 60 children and families over 12 months. Recruitment targeted families at 
four outpatient clinics where a child had been recently diagnosed with a CPC. Participating 
clinicians were the first to have contact with eligible families, providing them with study details 
for participation.  
Study inclusion criteria required that the child was aged 6 to 16 years, was diagnosed 
with asthma, diabetes, epilepsy, food allergy or juvenile idiopathic arthritis no more than 6 
months before recruitment, and that at least one parent could read English. The study aimed to 
recruit 12 children per chronic condition, for a total of 60 children with their families. Minimum 
age criterion was specified based on the minimum age that was valid for the study measures, and 
maximum age criterion was specified to ensure children did not transition into adult care during 
the study. Inclusion criterion for diagnoses of child chronic conditions was specified to represent 
the most common CPCs in children.14 English skills in parents were required because not all 
study measures have been validated in other languages. Children diagnosed with a degenerative 
neurological disorder were excluded.  
Data Collection 
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Study investigators followed up with eligible consenting families to schedule a 
convenient time for a telephone interview to assess child mental disorder, and surveys were 
mailed to parents at baseline and six months to measure psychosocial outcomes and demographic 
characteristics. Child mental disorder was assessed again at six months by telephone interview. 
All parents provided proxy reports for their children, and children who were at least 11 years of 
age self-reported for mail surveys and telephone interviews. Specific details about how study 
measures were used are explained below, and more details about the REACH study are 
documented elsewhere.121 
Analyses in the current study were conducted on data from parent and clinician reports.121 
Though 62 families were contacted to participate in the REACH study, 50 participated and 44 
were retained. Parent reports provided data for 50 children at baseline and 44 at the six-month 
follow-up. Participation and retention were better among clinicians; their reports provided data 
for 55 children at baseline and 51 at follow-up. While an appropriate sample size for validating 
single-item scales has not been substantiated, generally increasing the number of items in a scale 
also increases the sample size required for robust validation testing.122 Moreover, pilot studies, 
such as the REACH study, involving initial scale development and validation do not require the 
same level of power as a comprehensive scale analysis.123,124 Guyatt et al.125 suggested that a 
sample size of n = 34 (paired observations) is sufficient to establish responsiveness if the scale is 
predicted to be moderately responsive (d ³ 0.5).126 Terwee et al.119 consider a sample size of at 
least n= 50 adequate for most validation tests. For validation in pilot studies, Johanson et al.123 
recommend having samples at least n=24, and they support the recommendation of Hertzog et 
al.127 n= 30 to n= 40 if study objectives primarily involve group comparisons, rather than 
intervention. Validation of single-item scales has involved samples as small as n = 9,128 n = 
35,129 n= 40,124 n = 71130 and n = 75.131 While scientific consensus on computing a priori sample 
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size is lacking,119,132 especially for single-item scales, these findings provide a helpful context for 
appraising practical significance of sample sizes for single-item validation studies. Notably, the 
sample here provided by the REACH study meets nearly all these sample size recommendations 
for initial scale validation. Further comments on statistical power of the tests in this study are 
provided in the analysis and discussion sections of this thesis. 
Measures 
Clinician Report: Immunologists completed severity assessments for children with 
asthma and food allergies, endocrinologists for children with diabetes, neurologists for children 
with epilepsy, and rheumatologists for children with juvenile idiopathic arthritis. These clinicians 
were asked to carefully read instructions before using the study severity measures, and 
otherwise, no further measurement training was provided. The clinician most familiar with the 
condition of the child completed the severity reports. Severity was measured using the GASI, the 
DUSOI and the VAS. The GASI is a single-item 7-point Likert scale that asks clinicians to rate 
the severity of a condition given a range of response options from ‘Not at all severe’ to 
‘Extremely severe’ (see Figure 1). The GASI was adapted from the single-item Global 
Assessment of Severity of Epilepsy (GASE) scale, which is valid and reliable10,11 and was 
specifically designed to improve upon existing multi-item scales by measuring all aspects of 
epilepsy severity.10 Unlike the GASE, the GASI uses the term “disease” rather than “epilepsy” 
when asking, “Taking into account all aspects of this patient’s [disease], how would you rate its 








The DUSOI includes four individual components of severity (symptoms, complications, 
prognosis, and treatability) and a composite score of the four severity components (see Figure 2). 
The four components of severity are each assessed using five-point scales, and the composite 
score is calculated as the summed four ratings divided by the total summed score possible. The 
DUSOI has been used in patients aged 4 months to 89 years,115 has demonstrated high reliability 
and clinical face validity,113,114 and demonstrated greatest clinical value for individuals with 
CPCs versus other conditions.115,116 Because extensive research surrounds validation of the 
DUSOI composite score, this score was used as the clinical anchor for condition severity in all 
final models and tests in this study. 
The VAS is a 50 mm horizontal line where the distance measured from the leftmost part 
of the line to the rater’s mark is converted into a score out of 100 (see Figure 3). The 0 mm 
endpoint is anchored by the phrase “lowest severity” and 50 mm by “highest severity”.113 The 
VAS measures multidimensional constructs133 and characteristics on a continuum134 while 
demonstrating consistent precision over time.135 Although commonly a self-report tool, there is 
evidence for valid use of the VAS by external raters. In one study, investigators used the VAS 
and a simple descriptive scale to measure functional capacity of patients with rheumatoid 
arthritis completing two different tasks, and there were significant correlations between the two 
scales for assessment of both tasks (ρ= 0.42; ρ= 0.54).136 When used by clinicians, the VAS 










Figure 3. The visual analogue scale 
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Parent Report: Parents used the KIDSCREEN-27 to report on child HRQL and study 
investigators administered the Mini International Neuropsychiatric Interview for Children and 
Adolescents (MINI-KID) with parents to screen for child mental disorder. The KIDSCREEN-27 
is a multidimensional HRQL instrument with 27 items measuring five domains: physical well-
being, psychological well-being, parent relations and autonomy, social support and peers, and 
school environment.137 Domain scores are generated from five-point Likert scale items and are 
converted to T-scores with a mean of 50 and a standard deviation of 10. Higher T-scores indicate 
better HRQL. In a large international sample, the KIDSCREEN-27 displayed excellent internal 
reliability (a > 0.78) and item discriminant validity (IDV > 80%), and reasonable structural 
validity (RMSEA= 0.069).137 Further testing in samples of children with and without CPCs 
confirmed acceptable test-retest reliability (ICC= 0.61-0.74), satisfactory criterion validity (r= 
0.71-0.96), and acceptable convergent and discriminant validity with other HRQL instruments.138 
The KIDSCREEN-27 has demonstrated low to moderate informant agreement between children 
with CPCs and their parents, with agreement improving over time.139 The KIDSCREEN-27 has 
also been found to demonstrate partial measurement invariance in a clinical sample of children 
with mental disorder and their parents.140 
The MINI-KID is a structured diagnostic interview that uses screening questions and skip 
patterns to screen for 24 child and adolescent mental disorders contained in the DSM-IV and 
ICD-10.141 The interview is conducted with children aged 6 to 17 years, their parents, or both, 
and takes approximately 30 minutes to administer.141 Not all MINI-KID modules were used in 
the REACH study. Rather, modules were used that screen for the most common mental disorders 
in children. The MINI-KID has been validated using the Schedule for Affective Disorders and 
Schizophrenia for School Aged Children-Present and Lifetime Version and demonstrated very 
good interrater reliability (AUC ³ 0.89), acceptable to excellent test-retest reliability (AUC ³ 
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0.75), acceptable to high sensitivity (0.43-1.00), and substantial to high specificity (0.73-1.00).142 
Confirmatory factor analysis provides evidence for convergent and discriminant validity of the 
MINI-KID using latent factors from the Brief Child and Family Phone Interview (BCFPI),142 
which is a validated measure of child mental disorder.143 Diagnostic agreement between the 
standard version of the MINI-KID and the parent-proxy version (MINI-KID-P) was higher in a 
sample containing primarily outpatients (k= 0.46-0.94)141 versus a primarily population-based 
sample (k= 0.05-0.33).142 Recent work comparing the validity of various diagnostic tools, 
including self-completed problem checklists like the KIDSCREEN-27, discusses how structured 
interviews are a suitable means for classifying child mental disorder in clinical research.144 
Analysis 
The following analyses were performed in SAS Studio 9.0.4. As would be expected in an 
outpatient sample, initial exploration of the data revealed that clinicians did not use the full range 
of ratings on the GASI scale (see Appendix B, Figures B1-B2). Clinician ratings of severity 
clustered primarily among the lowest 5 ordinal outcomes and were characterized by a positively 
skewed distribution. Therefore, final tests and models were conducted using analytic methods 
best suited for ordinal categorical outcomes and nonparametric distributions. Granted most 
studies involving 7-point Likert scales use tests assuming continuous outcomes, Appendix C 
contains results of the following analyses using tests that assume a continuous outcome. 
Including results of the continuous outcome analyses extends the metric for comparison with 
other studies and further substantiates the findings of final models and tests contained in the 
main body of this thesis.56 
 Construct Validity: Concurrent validity of the GASI was assessed by measuring the 
correlation of GASI ratings with scores on the DUSOI and VAS using Kendall’s Tau-c (tc)145–148 
correlation coefficient. The Tau-c is ideal for large frequency tables and is recommended for 
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tables that are not square. Correlations were calculated using scores at baseline and six months. 
Cohen’s conventions were used to interpret tc= 0.10-0.30 as weak correlation, tc= 0.30-0.50 as 
moderate, and tc > 0.50 as strong,118 while also keeping in mind that Tau-c has been considered 
by some to be an overly conservative estimate of correlation.149 
Furthermore, strength of association with the VAS and DUSOI were measured using 
generalized linear modeling and logistic regression. In these models, area under the receiver 
operating characteristic curve (AUC) demonstrated the overall strength of association and 
regression coefficients evaluated the contribution of individual terms in the model. AUCs less 
than 0.5 were interpreted as the association being no better than chance, 0.5 to 0.7 as a weak 
association, 0.7 to 0.9 as moderate, and over 0.9 as strong.56 Final models accounted for (a) 
random variance introduced by time (baseline to six months), (b) random variance correlated 
among like diagnoses, which simultaneously accounted for the type of treating clinician, and (c) 
the potential confounding effects of child age. Age of a child can potentially affect how a 
clinician approaches the severity assessment and possibly influence complexity of the 
assessment. For example, among the chronic conditions included in this sample, age has shown 
to be associated with the type of symptoms experienced by children.150,151 Furthermore, some 
symptoms that emerge at these ages are very difficult to discern.152 With the other model 
adjustment, cluster sizes in the random effects statement were unbalanced after nesting children 
within their diagnoses. Potential bias from unbalanced clusters was accounted for by both the 
internal SAS syntax of PROC GLIMMIX153–157 and by the Kenward-Roger correction for 
denominator degrees of freedom.153 
Discriminant validity of the GASI was assessed using the KIDSCREEN-27 and the 
DUSOI. The KIDSCREEN-27 is suitable for discriminant validation because some domains on 
this instrument are intrinsically related to condition severity and others less so. Kendall’s Tau-c 
 24 
was used to measure correlation of GASI ratings with scores on different domains of the 
KIDSCREEN-27, testing functional bounds of the GASI.158 It was hypothesized that the GASI 
would correlate weakly (tc= 0.10-0.30) with the KIDSCREEN-27 domains representing 
unrelated constructs (Parent Relations and Autonomy, Social Support and Peers, School 
Environment). Weak correlation with these domains would support divergent validity. Evidence 
for convergent validity required at least moderate correlation (tc > 0.30) with the KIDSCREEN-
27 domains more representative of condition severity (Psychological Well-being, Physical Well-
being). Additionally, because the GASI is a global assessment, correlation with the VAS and 
DUSOI composite score was hypothesized to be stronger than correlation with individual items 
on the DUSOI.120 
“Discriminative” validation tested whether the scale was able to discriminate between 
children with multimorbidity versus children without multimorbidity. Multimorbidity was coded 
as screening positive for mental disorder using the MINI-KID. Fisher’s Exact test was performed 
on GASI ratings from the group of children with multimorbidity and from the group with no 
multimorbidity. Tests were performed using baseline and six-month ratings. A p-value less than 
0.05 was required to demonstrate ability of the GASI to discriminate between patients with and 
without multimorbidity. 
 Test-retest Reliability: Support of test-retest reliability required that GASI ratings did not 
change from baseline to six months in the subgroup of patients whose conditions remained stable 
throughout the study according to the DUSOI and VAS, the established clinical measures.11 
Establishing reliability provides evidence for minimal measurement error when using the GASI, 
and is a necessary prerequisite for assessing the responsiveness of a scale.56 In order to 
understand which dimensions of severity the GASI measures reliably over time, multiple tests 
were conducted using different items from the DUSOI. Patient subgroups were classified as 
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“stable” according to the clinical anchor used in each test-retest analysis. Table 1 reports the 
“stable” criteria that were applied to the data in order to conduct test-retest analyses using the 
Kappa coefficient, weighted Kappa, and the intraclass correlation coefficient (ICC). 
 
Table 1 – Criteria for Stable Severity as Defined by Study Measures  
  
Criteria when computing Kappa 
 Criteria when computing 
Weighted Kappa and ICC 
“Stable” defined 
by the DUSOI 
When using DUSOI items 
(symptoms, complications, 
prognosis, treatability): 
o Item rating must not 
change from low (<2) to 
high (≥2), or vice versa 
When using DUSOI composite 
score: 
o Item rating must not 
change from low (<40%) to 
high (≥40%), or vice versa 
When using DUSOI items 
(symptoms, complications, 
prognosis, treatability): 
o Must have no change in 
item rating 
 
When using DUSOI composite 
score: 
o Must have <8.3% 
change in score 
“Stable” defined 
by the VAS 
Rating must not change from low 
(<40%) to high (≥40%), or vice 
versa 
Must have <10.9% change in 
the rating 
 
ICC= intraclass correlation coefficient 
 
As dichotomization is necessary for computing the Kappa coefficient, the criterion used 
to classify stable patients using the DUSOI items was primarily based on the descriptions of high 
and low severity that were evident in the scale options. Because severity of the study sample 
clustered at the lower end of all the severity scales, cut-points for stability in the DUSOI 
composite score and VAS were placed toward the lower end of the scale to ensure reasonable 
sizes of dichotomized groups. Group sizes were afterward verified by assessing the distributions 
of severity ratings. For GASI ratings, it seemed appropriate to dichotomize by aggregating 
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ratings from “Not at all severe” to “A little severe” (Low severity) and “Somewhat severe” to 
“Extremely severe” (High severity), in consideration of the right-skewed distribution of severity 
in the sample. 
For analysis with the weighted Kappa and ICC, the rational for criteria used to classify 
stable patients using individual DUSOI items was based on evidence that clinically important 
change can be represented by approximately half a point change in a 7-point Likert scale.159 
Therefore, any change observed in the DUSOI item would be clinically meaningful. 
Additionally, response options for these items possess clinical descriptions that intrinsically 
demonstrate clinical importance with a mere one-point change. Clinical stability is not intuitively 
observed in the DUSOI composite and VAS ratings and was estimated using other methods. 
Common cut-point estimates for clinical stability include half a standard deviation in scale 
scores160 or 0.5 change in a 7-point Likert scale.159 The latter cut-point estimate was redefined as 
an 8.3% change because the DUSOI composite and VAS are not 7-point Likert scales, and was 
performed using an equidistant transformation of the cut-point 
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as suggested by Svensson.63 The primary indicator of a valid cut-point is that it yields rates 
similar to the referenced norm.56,57 Presented below is the rational for using different cut-points 
when assigning clinically stable subgroups using the DUSOI composite score and the VAS. 
The referenced norm cut-point for identifying clinical stability was “no change in 
individual DUSOI items”. Because the DUSOI is an established clinical measure its use as the 
referenced norm improved the quality of reliability testing119 and potentially prevented false-
negative test-retest results.161 The four individual DUSOI items yielded clinically stable 
subgroups with a mean of n= 32.5 and a median of n= 32, roughly representing the norm size for 
a stable subgroup in this sample. In comparison, the half a standard deviation cut-point estimate 
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yielded n=8 for the DUSOI composite and n=28 for the VAS, while the 0.5 change on 7-point 
scale (~8.3% change) estimate yielded n=29 for the DUSOI composite and n=24 for the VAS. In 
sum, the latter estimate better resembles the norm rates when using the DUSOI composite, and 
the former estimate better resembles the norm rates when using the VAS. The half a standard 
deviation estimate is sometimes too stringent when most individuals in the sample have low to 
moderate levels of impairment, in this case severity, and are less likely to make large 
improvements.160 This effect may be stronger in composite scores compared to single ratings like 
the VAS, and may explain why half a standard deviation was not a suitable cut-point for the 
DUSOI composite score in this sample. 
  Using the clinically stable subgroups, test-retest reliability was first assessed using the 
Generalized McNemar test.148,162 Generalized McNemar statistics with a p-value greater than 
0.05 provided initial evidence that GASI ratings in the stable subgroup did not change from 
baseline to six months. Next, the Kappa and weighted Kappa coefficients with 95% confidence 
intervals were used to assess reliability of measurements over time.56,126 A Kappa coefficient less 
than or equal to 0 is typically interpreted as poor agreement, .01 to .20 as slight, .21 to .40 as fair, 
.41 to .60 as moderate, .61 to .80 as substantial, and .81 to 1 as almost perfect.163 A Kappa 
coefficient of at least 0.70 was necessary to establish reliability of the GASI.126,164 Weighted 
Kappa was computed using quadratic (Fleiss-Cohen) weights165 as they are appropriate for 
ordinal outcomes with potentially large tables166 and allow for meaningful comparison with the 
ICC.56,167 Indeed, when the sample is large enough (n ³ 40)165 the ICC and quadratic weighted 
Kappa are identical.56 Because meaningful interpretation of weighted Kappa is often lost by 
differential weighting schemes,163 this study advocates the use of Kappa quadratic weights for 
future reliability testing of the GASI when the ICC cannot be used. The test-retest ICC is not 
appropriate for analyzing ordinal categorical outcomes when the sample is not large.163,165,168 
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Fortunately, both Kappa and weighted Kappa are measures of absolute agreement167,169 and 
therefore meet criteria for robust test-retest designs.170,171 
 Responsiveness: Internal responsiveness was first assessed using a distribution-based 
approach where the standardized response mean117 (SRM) was computed. Distribution-based 
assessment of responsiveness was required172 because there is no ideal gold-standard severity 
scale to function as an anchor for assessing responsiveness. The SRM was calculated by dividing 
mean change in GASI ratings from 0 to 6 months by standard deviation of change ratings during 
that time. Using the SRM, as opposed to t-tests, removes reliance on sample size117 and provides 
a within-person assessment of change.172 In the absence of a normal distribution, a bootstrap 
procedure was implemented to obtain an approximate distribution from which to compute the 
SRM point estimate and 95% confidence intervals with interpretation using Cohen’s conventions 
(d= 0.2; 0.5; and 0.8) for small, medium and large magnitude of responsiveness.173 
Next, an anchor-based approach was used to measure responsiveness. Using a clinically 
anchored subset of “changed” scores (DUSOI scores that did not qualify as “stable”),11 Guyatt’s 
responsiveness index125 (GRI) was calculated to assess ability of the GASI to detect clinically 
important changes in condition severity.117 The GRI is the ratio of average change scores of 
changed patients divided by the standard deviation of the change scores in stable patients, and 
was interpreted using Cohen’s effect size conventions as previously mentioned. 
Sensitivity/Specificity: The AUC, calculated by generalized linear and logistic regression 
models, indicated ability of GASI to discriminate between “stable and “changed” patients using 
change criteria defined by the DUSOI.11,117 An AUC less than 0.5 was interpreted as 
sensitivity/specificity being no better than chance, 0.5 to 0.7 as low, 0.7 to 0.9 as moderate, and 
over 0.9 as high.56,174 Model adjustments for child characteristics were identical to those applied 




 The mean age of children in the study sample was 11.3 years (SD= 3.3) and, overall, both 
sexes were almost equally represented (47.3% males). At baseline (n= 55), the majority of 
children were diagnosed with asthma (n= 16), and then followed by juvenile arthritis (n= 12), 
diabetes (n= 11), epilepsy (n= 8), and food allergy (n= 8). Among these children, 58.2% 
screened positive for mental disorder. At the six-month follow-up, minimal attrition was 
observed (n= 4), and while the proportions of CPCs represented in the sample was nearly 
unchanged, there was a lower prevalence of multimorbidity (42.9%). Median severity ratings for 
food allergy were higher than or equal to all other diagnoses for all severity scales at baseline 
and six months, while median severity ratings for diabetes were always the lowest. Table 2 
contains additional details of the study sample. 
Construct Validity 
 Concurrent Validity: Table 3 contains results of Kendall’s Tau-c correlation between the 
GASI and established severity measures. All correlations with the GASI were significant (p ≤ 
.001) at baseline (tc1) and six months (tc2), with the exception of the DUSOI items Symptoms 
and Complications which were not statistically significant. As hypothesized, correlations were 
strongest with the DUSOI composite score (tc1= 0.63, CI= 0.51-0.76; tc2= 0.57, CI= 0.46-0.69) 
and the VAS (tc1= 0.78, CI= 0.67-0.88; tc2= 0.78, CI= 0.65-0.91), providing evidence for 
convergent validity. The correlation with Prognosis was also strong (tc1= 0.64, CI= 0.50-0.77; 
tc2= 0.68, CI= 0.56-0.80). Nearly identical patterns of correlation magnitude and statistical 
significance were found when this analysis was performed using Spearman’s rank correlation 
(see Appendix C, Table C1).
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Table 2 – Sample Characteristics and Severity Scoring at Baseline and 6 Months 
 
Full Sample Food Allergy Asthma Diabetes Epilepsy Juvenile Arthritis 
Baseline 
n 55 8 16 11 8 12 
Age, mean (SD) 11.3 (3.3) 10.2 (3.4) 10.3 (3.3) 13.7 (1.7) 12.8 (2.1) 11.5 (2.8) 
Male, n (%) 26 (47.3) 7 (87.5) 5 (31.25) 3 (27.3) 7 (87.5) 4 (33.3) 
Multimorbid, n (%) 32 (58.2) 5 (62.5) 10 (62.5) 6 (54.6) 4 (50.0) 7 (58.3) 
Condition Severity       
         GASI, median (IQR) 16.7 (33.3) 41.7 (25.0) 16.7 (25.0) 0.0 (0.0) 33.3 (33.3) 16.7 (41.7) 
         DUSOI, median (IQR) 37.5 (12.5) 37.5 (0.0) 37.5 (9.4) 18.8 (18.8) 31.3 (21.9) 37.5 (18.8) 
         VAS, median (IQR) 16.3 (41.0) 45.3 (30.7) 16.7 (52.6) 0.0 (4.4) 33.8 (38.7) 18.2 (42.3) 
Six Months 
n 51 8 15 10 7 11 
Multimorbid, n (%) 21 (42.9) 2 (25.0) 9 (60.0) 1 (11.1) 4 (50.0) 5 (55.6) 
Condition Severity       
         GASI, median (IQR) 16.7 (33.3) 83.3 (0.0) 16.7 (16.7) 0.0 (0.0) 16.7 (33.3) 16.7 (50.0) 
         DUSOI, median (IQR) 31.3 (18.8) 43.8 (0.0) 37.5 (12.5) 12.5 (12.5) 25.0 (6.3) 31.3 (12.5) 
         VAS, median (IQR) 19.8 (47.0) 85.9 (5.3) 15.6 (26.0) 7.6 (17.4) 17.8 (17.6) 18.2 (36.8) 
 
For comparison, all severity scores have been standardized to a scale of 0 (lowest severity) to 100 (highest severity). 
IQR= interquartile range
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Table 3 – Concurrent Validity Assessed by Kendall’s Tau-c Correlation 
  Baseline  6 Months 
Severity Measure tc (95% CI) p-Value n tc (95% CI) p-Value n 
DUSOI: Symptoms 0.24 (-0.00, 0.47) 0.051 51 -0.04 (-0.28, 0.21) 0.753 51 
DUSOI: Complications 0.05 (-0.04, 0.14) 0.267 50 0.06 (-0.07, 0.19) 0.353 51 
DUSOI: Prognosis 0.64 (0.50, 0.77) <.001 53 0.68 (0.56, 0.80) <.001 51 
DUSOI: Treatability 0.26 (0.11, 0.41) 0.001 52 0.38 (0.20, 0.56) <.001 51 
DUSOI: Composite 0.63 (0.51, 0.76) <.001 49 0.57 (0.46, 0.69) <.001 51 
VAS 0.78 (0.67, 0.88) <.001 52 0.78 (0.65, 0.91) <.001 51 
 
Kendall’s Tau-c correlation coefficients (tc) are reported with 95% confidence intervals at baseline and 6 months for correlation of the GASI with 
individual DUSOI items, the DUSOI composite score, and the VAS.
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Table 4 contains the results of unadjusted and adjusted regression models assessing the 
strength of association between the GASI (dependent variable) and the DUSOI composite score 
(independent variable) at baseline (AUC1) and six months (AUC2). The unadjusted models 
demonstrated moderate to strong associations between the GASI and DUSOI composite score 
(AUC1= 0.88, CI= 0.79-0.98; AUC2= 0.83, CI= 0.70-0.95). After adjusting for correlated random 
effects within diagnosis groups (nested effects), the baseline AUC increased (AUC1= 0.94, CI= 
0.85-1.00), but the AUC in the six-month model decreased (AUC2= 78, CI= 0.64-0.92). Further 
adjusting the model for child age resulted in improvement in the baseline model (AUC1= 0.96, 
CI= 0.92-1.00) and in the six-month model (AUC2= 0.86, CI= 0.75-0.97). 
 In the longitudinal models (see Table 5), the unadjusted AUC again demonstrated a 
moderate to strong association between the GASI and the DUSOI composite score (AUC= 0.85, 
CI= 0.77-0.93). Magnitude of the AUC was further increased after adjusting for nested random 
effects (AUC= 0.94, CI= 0.89-0.99), but the AUC was unaffected by the addition of the 
covariate for child age. Because the DUSOI composite score is the most validated and provides 
the most parsimonious model, its results are shown here and provide the main support for 
concurrent validity of the GASI. Results for the joint model with all DUSOI items and for the 
model with independent associations with severity scales also demonstrated strong associations 
overall (see Appendix A, Tables A1-A3). This reflects what is also found for associations 
measured using multiple linear regression (see Appendix C, Tables C2-C4) and further supports 
concurrent validity of the GASI. 
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Table 4 – Concurrent Validity Assessed by AUC in Unadjusted and Adjusted Regression Models 
 
Independent Variables 
 Baseline  6 Months  
Model Est. (SE) n AUC (95% CI) Est. (SE) n  AUC (95% CI) 
1 DUSOI 23.07 (2.88)† 49 0.88 (0.79, 0.98) 11.20 (3.68)† 51 0.83 (0.70, 0.95) 
2 (nested) DUSOI 23.05 (7.65)† 49 0.94 (0.85, 1.00) 11.21 (3.71)† 51 0.78 (0.64, 0.92) 
3 (nested) DUSOI 31.39 (11.79)* 44 0.96 (0.92, 1.00) 11.27 (3.83)† 49 0.86 (0.75, 0.97) 
 Child Age 0.49 (0.22)* -- -- 0.07 (0.12) -- -- 
 
Area under the receiver operating characteristic curve (AUC) is reported for each step of constructing the fully adjusted model. AUCs demonstrate 
strength of association between the GASI (dependent variable; dichotomized as Low/High severity) and the DUSOI composite score. The GASI 
was dichotomized by aggregating ratings from “Not at all severe” to “A little severe” (Low severity) and “Somewhat severe” to “Extremely severe” 
(High severity). Models 2 and 3 include a nested random effects statement identifying children within their treating clinician. Parameter estimates 
are only significant where noted. *p<.05, †p<.01 
Est.= Estimate 








Table 5 – Concurrent Validity Assessed by AUC in Longitudinal Unadjusted and Adjusted Regression Models 
Model Independent Variables Estimate SE p-Value n AUC (95% CI) 
1 DUSOI 11.15 2.64 <.001 100 0.85 (0.77, 0.93) 
2 (nested) DUSOI 13.80 3.48 <.001 100 0.94 (0.89, 0.99) 
3 (nested) DUSOI  14.96 3.74 <.001 93 0.94 (0.89, 0.99) 
 Child Age 0.20 0.11 0.069 -- -- 
 
Area under the receiver operating characteristic curve (AUC) is reported for each step of constructing the fully adjusted model. AUCs demonstrate 
strength of association between the GASI (dependent variable; dichotomized as Low/High severity) and the DUSOI composite score by assessing 
both GASI and DUSOI measurements performed at baseline and 6 months while controlling for time (baseline to six months). GASI 
dichotomization and nested random effects are equivalent to Table 4. 




Discriminant Validity: Table 6 displays the results of discriminant validity testing for 
correlation (tc) of the GASI with individual domains on the KIDSCREEN-27. All correlations 
were nonsignificant at baseline and six months (p-value > 0.05). Divergence was observed 
among baseline tests, with weak correlations ranging from tc= -0.004 for Parents and Autonomy 
to tc= -0.10 for Social Support and Peers. Negative correlations were observed for all baseline 
measures, indicating that as condition severity increased, HRQL decreased. At six months, 
correlations with all KIDSCREEN-27 domains were weak (tc= -0.12-0.08) and the direction of 
relationships differed across KIDSCREEN-27 domains. These same patterns of correlation 
strength and direction of relationship were found when analysis was performed using 
Spearman’s rank correlation (see Appendix C, Table C5). 
 Discriminative Validity: The results of Fisher’s Exact tests for discriminative validity of 
the GASI are reported in Table 7. Because the initial frequency table had low cell counts, a 
second table was created with aggregated GASI ratings to ensure associations between the GASI 
and presence of multimorbidity were adequately tested. GASI ratings did not discriminate 
between children with and without multimorbidity (p-value > 0.05). This finding is also 








Table 6 – Discriminant Validity Assessed by Kendall’s Tau-c Correlation 
KIDSCREEN-27 Domain 
 Baseline  6 Months 
tc (95% CI) p-Value n tc (95% CI) p-Value n 
Physical Well-being -0.02 (-0.25, 0.20) 0.851 48 0.08 (-0.14, 0.30) 0.483 44 
Psychological Well-being -0.07 (-0.27, 0.13) 0.485 49 -0.08 (-0.36, 0.19) 0.556 43 
Parents and Autonomy -0.004 (-0.22, 0.21) 0.968 48 0.05 (-0.18, 0.29) 0.665 44 
Social Support and Peers -0.10 (-0.30, 0.11) 0.345 49 -0.08 (-0.33, 0.18) 0.546 44 
School Environment -0.08 (-0.29, 0.14) 0.490 46 -0.12 (-0.38, 0.15) 0.381 43 
 
Kendall’s Tau-c correlation coefficients (tc) are reported with 95% confidence intervals at baseline and 6 months for correlation of the GASI with 












Table 7 – Discriminative Validity Assessed by Fisher’s Exact Test of Independence 
Frequency Table 
 Baseline  6 Months 
Table Probability (P) p-Value n Table Probability (P) p-Value n 
(a) Multimorbidity (yes/no) x GASI (0 – 4) <.001 0.096 55 0.003 0.527 51 
(b) Multimorbidity (yes/no) x GASI (0 – 2) 0.028 0.476 55 0.022 0.343 51 
 
The results of Fisher’s Exact test for two frequency tables are reported. Frequency tables were analyzed at baseline and six months using data in 
(a) raw and (b) aggregated format. Frequency table details: (a) Two columns pertain to presence of multimorbidity (No Multimorbid, Yes 
Multimorbid) and five rows pertain to GASI ratings (0=Not at all severe; 1=A little severe; 2=Somewhat severe; 3=Moderately severe; 4=Quite 
severe/Very severe); (b) Two columns pertain to presence of multimorbidity (No Multimorbid, Yes Multimorbid) and three rows pertain to GASI 





 Tables 8-10 contain results for test-retest reliability. Generalized McNemar’s test 
demonstrated no change in GASI ratings from baseline to six months for all stable subgroups 
defined by individual DUSOI items, the DUSOI composite score and the VAS (p-value > 0.05). 
These findings are equivalent to results from the analysis using Wilcoxon signed rank test (see 
Appendix C, Table C7). 
According to the Kappa coefficient, which examined the reliability of change in the 
GASI for ratings that change from low to high, or high to low, strength of agreement in GASI 
ratings ranged from moderate (k= 0.57, CI= 0.32-0.82) for stable subgroups defined by 
Treatability to almost perfect (k= 0.87, CI= 0.69-1.00) for stable subgroups defined by the VAS. 
Similar to the VAS subgroup, substantial agreement was demonstrated using GASI ratings from 
the stable subgroup defined by the DUSOI composite score (k= 0.79, CI= 0.51-1.00). Similar to 
the tests for construct validity, the magnitude of Kappa coefficients were highest when 
incorporating severity scales more related to global severity. 
Weighted Kappa tests, which examined the reliability of smallest changes possible in 
GASI ratings, generated smaller reliability coefficients than Kappa tests. Agreement ranged from 
moderate (kw= 0.45; CI= 0.15-0.75) in the Treatability subgroup to almost perfect (kw= 0.81, 
CI= 0.64-0.99) in the VAS subgroup. Agreement between GASI ratings at baseline and six 
months was moderate for the subgroup defined as stable according to the DUSOI composite 
score (kw= 0.57, CI= 0.36-0.78). These weighted Kappa results closely reflect findings from the 
test-retest analysis using bootstrapped ICCs (see Appendix C, Table C8). 
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Table 8 – Test-retest Reliability Assessed by Generalized McNemar’s Test of Homogenous 
Distributions 
Measure Defining Stable Subgroup Test Statistic (GMN) DF p-Value n 
DUSOI: Symptoms 4.32 3 0.229 27 
DUSOI: Complications 8.88 4 0.064 38 
DUSOI: Prognosis 1.14 3 0.767 30 
DUSOI: Treatability 2.37 4 0.667 34 
DUSOI: Composite 9.17 4 0.057 29 
VAS 2.67 3 0.446 28 
 
The results of Generalized McNemar’s Test for six frequency tables are reported. Frequency tables were 
constructed using GASI ratings from children in the Stable subgroup. Stable is defined by individual 
DUSOI items, the DUSOI composite score, and the VAS (see Table 1). 
DF= Degrees of freedom 
 
Table 9 – Test-retest Reliability Assessed by Kappa Coefficient 
Measure Defining Stable Subgroup k (95% CI) n 
DUSOI: Symptoms 0.63 (0.37, 0.90) 37 
DUSOI: Complications 0.64 (0.39, 0.88) 43 
DUSOI: Prognosis 0.64 (0.39, 0.90) 35 
DUSOI: Treatability 0.57 (0.32, 0.82) 45 
DUSOI: Composite 0.79 (0.51, 1.00) 29 
VAS 0.87 (0.69, 1.00) 36 
 
Kappa coefficients (k) with 95% confidence intervals (CI) are reported. Coefficients were computed using 
GASI ratings from children in the Stable subgroup. Stable is defined by individual DUSOI items, the 
DUSOI composite score, and the VAS (see Table 1). GASI dichotomization is equivalent to the 
description in Table 4. 
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Table 10 – Test-retest Reliability Assessed by Weighted Kappa Coefficient 
Measure Defining Stable Subgroup kw (95% CI) n 
DUSOI: Symptoms 0.62 (0.43, 0.81) 27 
DUSOI: Complications 0.53 (0.31, 0.75) 38 
DUSOI: Prognosis 0.63 (0.46, 0.80) 30 
DUSOI: Treatability 0.45 (0.15, 0.75) 34 
DUSOI: Composite 0.57 (0.36, 0.78) 29 
VAS 0.81 (0.64, 0.99) 28 
 
Kappa coefficients with quadratic weights (kw) and 95% confidence intervals (CI) are reported. 
Coefficients were computed using GASI ratings from children in the Stable subgroup. Stable is defined by 





 Results for responsiveness of the GASI are found in Table 11. Distribution-based 
responsiveness, as measured by the SRM, demonstrated ability of GASI ratings to respond to 
meaningful changes in condition severity where meaningful change was defined by the 
distribution of change magnitude observed in the sample. Therefore, based on a bootstrapped 
distribution of GASI ratings at baseline and six months, the GASI demonstrated a large 
magnitude of responsiveness (SRM= 0.84, CI= 0.68-1.11). Anchor-based responsiveness, as 
measured by the GRI, demonstrated ability of GASI ratings to respond to change in severity 
where change was defined by external anchors. As explained in the methods section, the external 
anchors that provided change definitions were the individual DUSOI items, the DUSOI 
composite score, and the VAS. According to the change that occurred in these anchors, the GASI 
demonstrated a medium (GRI= 0.77, CI= 0.24-1.47) to large (GRI= 3.83, CI= 2.65-6.27) ability 
to detect change in condition severity. Importantly, the magnitude of responsiveness in the GASI 
was large when change was defined by the clinical anchor, the DUSOI composite score (GRI= 
0.83, CI= 0.29-1.70). 
Sensitivity/Specificity 
 Table 12 describes the models and results for regression analysis of sensitivity/specificity 
of the GASI. In the unadjusted model, the AUC confidence interval dipped just below the null 
value (AUC= 0.5), suggesting that the ability of the GASI to discriminate between change and 
no change in condition severity is no better than chance (AUC= 0.62, CI= 0.46-0.77). Adjusting 
for diagnosis (nesting child in clinician) improved magnitude of this estimate (AUC= 0.78, CI= 
0.63-0.92), and resulted in a model that satisfied the a priori requirement for adequate 
sensitivity/specificity. Further adjusting the model for child age increased the AUC again (AUC= 
0.81, CI= 0.68-0.94). 
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Table 11 – Responsiveness Assessed by Standardized Response Mean and Guyatt’s 
Responsiveness Index 
Responsiveness Test Test Statistic (95% CI) n 
Standardized Response Mean 0.84 (0.68, 1.11) 51 
GRI when change defined by:   
DUSOI: Symptoms 1.09 (0.51, 1.96) 47 
DUSOI: Complications 0.77 (0.24, 1.47) 46 
DUSOI: Prognosis 1.01 (0.56, 1.64) 49 
DUSOI: Treatability 1.74 (0.83, 2.94) 48 
DUSOI: Composite 0.83 (0.29, 1.70) 45 
VAS 3.83 (2.65, 6.27) 48 
 
The results of distribution- and anchor-based responsiveness statistics with bootstrapped 95% confidence 
intervals (CI) are reported as the standardized response mean and Guyatt’s Responsiveness Index 















Table 12 – Sensitivity/Specificity Assessed by AUC in Unadjusted and Adjusted Regression 
Models 
Model Independent Variables Estimate SE p-Value n AUC (95% CI) 
1 DGASI 0.29 0.21 0.179 45 0.62 (0.46, 0.77) 
2 (nested) DGASI 0.29 0.22 0.196 45 0.78 (0.63, 0.92) 
3 (nested) DGASI 0.28 0.23 0.223 43 0.81 (0.68, 0.94) 
 Child Age -0.04 0.11 0.747 -- -- 
 
Area under the receiver operating characteristic curve (AUC) is reported for each step of constructing the 
fully adjusted model. AUCs demonstrate the magnitude of sensitivity/specificity of the GASI when 
identifying “change” or “no change” in condition severity. Condition severity was considered “changed” if it 
did not meet criteria for stability as defined by the DUSOI composite score (see Table 1; “Computing 
Weighted Kappa and ICC”). Models 2 and 3 include a nested random effects statement identifying 
children within their treating clinician. 
DGASI= (GASI ratings at six months) – (GASI ratings at baseline) 





 In response to the limitations of current severity assessments, this study provided 
evidence for validity of the GASI—a scale developed to improve brief global assessment of 
severity in children with CPCs. In brief, the GASI was found to be valid, reliable, and 
responsive. The scale demonstrated appropriate associations with established severity measures 
and was able to detect changes in condition severity, doing so with minimal measurement error. 
As intended in its development, the GASI had a precise scope of measurement. Its ratings 
reflected condition severity rather than other potentially related constructs such as HRQL or 
presence of mental disorder. 
 Construct Validity: The GASI demonstrated excellent construct validity, including 
concurrent and discriminant features, establishing that it measures what it purports to measure—
the global severity of CPCs. Concurrent validity was robust regardless of model adjustments for 
diagnosis (treating clinician) and child age, providing evidence that using the GASI across 
children aged 6-17 years with different CPCs is valid. 
The GASI did not have a perfect association with the DUSOI composite score, which 
suggests the two scales measure severity somewhat differently. This could potentially be 
explained by the fact that the GASI was designed to measure global severity where the weighting 
of individual aspects of severity is inherently performed by the clinician. In contrast, the DUSOI 
composite score measures severity constructs that are both specific (e.g., complications) and 
global (e.g., prognosis), and does so in an unweighted manner. Indeed, the GASI converged with 
Prognosis and diverged with the DUSOI’s potentially less “global” items, Symptoms and 
Complications. In the current sample, the DUSOI item Symptoms may also be less relevant 
because (a) the study clinicians found its meaning ambiguous for the conditions being assessed, 
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and (b) clinicians have previously ranked it as less helpful for assessing chronic conditions 
compared to acute conditions.116 
The strongest relationships among scales were observed between the GASI and the VAS. 
This could potentially be explained by them both being single-item scales, neither being distorted 
by items or indicators less related to global severity. The small degree of weakness observed in 
the relationship between the GASI and the VAS could be explained by a number of factors. For 
example, the area to place ratings for the GASI is about twice as large as that for the VAS, which 
may have caused clinicians perceived the magnitude of severity to be greater at the endpoints of 
the GASI compared to the endpoints of the VAS. Research also shows that VASs are prone to 
“end-of-scale” effects, where ratings trend toward ends of the scale, and that Likert scales are 
prone to “middle-of-scale” effects, where ratings trend toward middle of the scale,175 which 
would temper associations between these scales. In addition, some discrepancies between the 
GASI and VAS could be attributed to random error.56 
 Divergent validity of the GASI is demonstrated by the absence of strong correlations with 
any domain of child HRQL. The overall lack of correlation observed corroborates findings from 
the recent pan-Canadian study on pediatric epilepsy where family factors were more relevant 
than severity when modeling HRQL.176,177 Although severity of a CPC may be a poor indicator 
of HRQL overall, observing no correlation with the HRQL domain relating to physical well-
being is somewhat surprising because there is a theoretical relationship between these constructs. 
In the current study, factors that may contribute to lack of correlation with the physical well-
being domain include (a) the potential masking/confounding effects of multimorbidity,178 for 
which investigation by regression was beyond the scope of this study, and (b) discrepancies 
known to exist between parent and clinician perspectives on child HRQL,179 which may also be 
relevant to physical and psychological domains. 
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 Fisher’s Exact test of independence demonstrated inability of the GASI to discriminate 
between children classified as multimorbid and not multimorbid. This is not surprising 
considering clinicians were directed to rate severity of children’s physical, not mental, 
conditions. Severity was not associated with multimorbidity in this sample, which contrasts with 
a recent report that the presence of mental disorder in youth was associated with higher levels of 
disability compared to youth with only physical conditions.180 
 Test-retest Reliability: This study provided evidence to support test-retest reliability of 
the GASI. First, reliability was supported by the generalized McNemar’s test, which provided 
reason to proceed with more rigorous reliability testing. Next, depending on which clinical cut-
point was used, the Kappa coefficient demonstrated a substantial to almost perfect magnitude of 
agreement. This means that in an outpatient population of children with CPCs, change observed 
from “low severity” to “high severity”, or vice versa, is meaningful and should not be attributed 
to measurement error.56 Furthermore, test-retest analyses using the weighted Kappa and the 
stability definition derived from the VAS demonstrated that any change in the GASI is 
meaningful. However, the same cannot be said when stability is defined by the DUSOI 
composite score, the study’s main clinical anchor. Moreover, because of small diagnosis 
subgroups in the weighted Kappa analyses, generalizability of these findings to various CPCs is 
limited. Therefore, current interpretation of the GASI should rely on low versus high severity 
ratings (as described above) rather than on minimum changes in the scale until additional 
research in this area is conducted. 
 Responsiveness: The GASI is highly capable of detecting meaningful change in condition 
severity. Some global severity scales have been known to demonstrate more responsiveness than 
measures tapping individual domains,57,120 which may explain the notably high responsiveness 
observed in the GASI. With test-retest reliability having established that changes observed in the 
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GASI are meaningful, responsiveness findings establish that the GASI can detect such changes 
in the severity of a CPC when they occur.56 
 Sensitivity/Specificity: The findings suggest that when the MCID is applied across 
different diagnoses, the GASI is unable to discriminate between change that is or is not clinically 
important. However, because the sensitivity/specificity regression models were adequately 
powered for making comparisons (n ≥ 44),56 comparison among these models indicates that this 
discriminative ability would be restored if factors related to diagnosis were controlled for. It is 
possible that the definition of MCID was not appropriate for every type of CPC in the sample. 
Criteria for MCID in a scale are often informed by characteristics of the diagnosed condition.181 
If future studies are unable to establish a MCID that is generalizable across multiple CPCs, 
MCID cut-points for the GASI will need to be established for individual diagnoses. However, the 
confidence interval computed in this study is wide and includes appropriate magnitudes of the 
AUC for sensitivity/specificity. This suggests that the current finding should not be considered 
conclusive, and that using the current MCID definition in a larger sample may demonstrate 
adequate sensitivity/specificity in the GASI. 
Implications 
The findings from this study have important implications for research and clinical 
practice. The GASI is able to compare severity across a number of different childhood CPCs and 
can therefore help fill gaps in comparative pediatric research. For example, in this study the 
GASI provided evidence that, on average, mental disorder had no effect on severity of CPCs in 
this sample. Follow-up research using the GASI could aim to replicate these findings and test 
whether the effect varies across different CPCs. When choosing a tool to assess severity, the 
GASI may better reflect global properties of severity than the DUSOI10 and may provide easier 
interpretation of severity than the VAS which has no categories to explain the different meanings 
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ratings.59 As a result, the GASI may provide a more suitable overall assessment of severity to, 
for instance, help clinicians understand the progress of chronic conditions,9 or help patients 
understand the effects of self-management.182,183 The GASI can also be used by researchers and a 
variety of healthcare stakeholders. 
With regards to its use in the clinical setting, the GASI is a simple and ultra-brief severity 
assessment that is ideal for busy practices. As such, the GASI could contribute to a solution 
surrounding the systems-level issue of deficient routine outcome monitoring. Routine outcome 
monitoring is advocated in the pediatric Chronic Care Model37 and has been shown to improve 
patient outcomes and reduce burdens on clinicians and healthcare systems.9 However, this 
activity is often hindered because clinical information systems essential to the Chronic Care 
Model are either missing, not used, or misused.184 In a study of 108 care teams that manage 
CPCs across the United States, the majority of care teams did not have a condition registry with 
which to track the progress of patients toward clinical goals.42 This problem also limits public 
health practice that uses data on patient outcomes over time.52,53 At a more nuanced level, even 
when clinical information systems are utilized, problems still exist at the point of clinician 
documenting.77,185–187 In a retrospective cohort study of 2,109 Canadian patients hospitalized for 
myocardial infarction, an investigation of clinician documentation quality found that only 58% 
of patient charts contained information on whether the patient had a previous history of heart 
failure, which should always be included in charts for these patients.185 The GASI could equip 
clinical information systems with a versatile scale allowing quick and simple outcome 
measurement and incentivize proper documenting of outcomes by clinicians. 
Study Strengths and Limitations 
Strengths of this study include a wide range of analyses useful for comparison with future 
investigations of the GASI. Evidence for the current findings is strengthened by convergence of 
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a priori hypotheses for the main analyses.56 The same can be said for the alternative analyses 
that were performed assuming continuous outcomes (see Appendix C). Tests were conducted on 
data from real clinical settings, compared to the common alternative of case vignettes or patient 
charts, and therefore supports use of the GASI in outpatient practices. The regression 
adjustments for child and clinician characteristics assisted interpretation of results and informed 
future directions for validating the GASI. This use of regression modeling is a demonstration of 
the validity generalization methodology developed by Hunter et al.188 Because this methodology 
is not widely used in scale validation, the present study is an important example of advanced 
applications in validation science, especially for studies with small samples. 
The following limitations may be found in this study. The form that was completed by 
clinicians contained all three severity measures, allowing for potential priming effects between 
scales. However, the effect of priming is likely to be minimal based on the different scale 
formats, the different question prompts across the scales, and the differential functioning 
observed between the scales (i.e., discriminant validity). Because there is no ‘gold standard’ 
severity scale for this population, the DUSOI is not a perfect clinical anchor. Ideal gold standards 
are rare172 and appropriate gold standards are difficult to find for most validation studies in the 
healthcare field.67 This means that construct validation requires additional forms of testing, as 
performed in this study using discriminant and discriminative validation56 with multiple severity 
scales87 and a priori hypotheses.55  
Generalizability of the findings may be limited by the relatively small sample. However, 
the sample size was typical for initial validation of single item scales and statistical power was 
adequate for all final models and tests, with the exception of the weighted Kappa analyses. These 
analyses, at times, had incomplete representation of diagnoses and sample sizes were just below 
the threshold (n= 30)170 recommended for interpreting conventional reliability indices. In 
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addition, missing data may bias the results of statistical analyses, especially because missing data 
bias has a stronger effect in small samples. Rates of missingness, and potential missing data 
biases, were greatest for discriminant analyses with the KIDSCREEN-27 (11%-16%) and for the 
fully adjusted AUC models (15%-20%) testing concurrent validity and sensitivity/specificity. 
However, missing data did not exceed 5% in the longitudinal concurrent validity AUC model or 
in any test that used only the six-month data. Multiple imputation was not used because little is 
known about its validity when missingness is less than 20% in small samples.189 Based on the 
pattern of missingness and on comments made by study clinicians, missing data is best explained 
by clinicians preferring not to use certain items on the DUSOI. 
External validity of the diagnosis subgroups is also limited. Although this study included 
the most common childhood CPCs,122 which is ideal for validation of a generic severity scale, 
only one female was present in each of the epilepsy and food allergy subgroups. However, it is 
not apparent that equal sex representation would yield findings different from the current study. 
For children with epilepsy, type of seizure is the only variable consistently related to sex,190,191 
and research in childhood food allergy has found that sex is not significantly related to 
prevalence or severity.192 With regards to age, both the epilepsy and diabetes subgroups included 
children who were ten years of age and older, and these children were more likely to be 
experiencing puberty.193 While puberty has negligible effect on epilepsy,194 it may increase 
diabetes related complications.150 However, there was no bias toward increased Complications or 
Symptoms (measured by the DUSOI) in the study subgroup with diabetes. Rather, like the other 
subgroups the diabetes subgroup had very low ratings for Complications and Symptoms. 
Additionally, limitations exist in the assessment of test-retest reliability. Retest after six 
months is reasonable for children with epilepsy whose conditions are expected to remain stable 
during this time.11 However, this may not be applicable for every CPC in the sample. I 
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ameliorated this issue by defining stability as having equivalent severity scores at baseline and 
six months on a highly reliable clinical anchor. This definition of stability meant that the overall 
contribution of severity determinants was equivalent at baseline and six months, but it did not 
guarantee that the proportional contribution of these determinants was equivalent at both times, 
which is typically assumed with shorter test-retest periods. Though this is a limitation of the 
current test-retest analysis, it is not likely to have a large affect findings surrounding the 
reliability of global ratings, such as in the GASI, in the same way it would affect ratings of 
individual aspects of severity. Finally, a long delay before retest has the benefit of preventing 
recall bias from invalidating test-retest results, especially for short scales56 like the GASI. 
Future Considerations 
The priority for future work is to further evaluate reliability of the GASI. Currently, the 
reliability findings only support use the GASI where ratings are interpreted in a binary sense 
(low versus high severity), which limits its utility. Future testing of inter-rater reliability may 
support interpretation of the full range of GASI ratings56 and also provide evidence for whether 
other clinicians, such as nurse practitioners, can reliably use the scale. Knowledgeable 
informants of condition severity also include children with CPCs and their parents, and future 
work should investigate whether they can reliably complete the GASI and whether those 
assessments are useful for research and routine clinical practice. Such analyses would ideally 
incorporate reliability generalization methodology to identify variables that affect the magnitude 
of reliability.56  
Additionally, further testing should examine whether current definitions for MCID can be 
used to establish sensitivity/specificity of the GASI in a larger sample, or whether diagnosis-
specific definitions for MCID are necessary. Overall, future validation studies will benefit from 
using larger samples where there is better representation of the age and sex within each diagnosis 
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subgroup. Understanding external validity of the GASI will also be improved by including only 
the GASI on study forms completed by clinicians (i.e., avoid priming effects) and through the 
collection of more diagnostic details surrounding diabetes (e.g., Type 1, Type 2) and epilepsy 
(e.g., temporal, complex partial, generalized). Future studies should assess missing data and 
acknowledge these diagnostic details when doing so. 
Effort should also be devoted to examining whether the GASI is a valid scale for other 
physical conditions in children. Furthermore, future work should also consider whether the GASI 
improves upon the limitations of current severity assessments in children with diagnosed mental 
disorders, with undiagnosed conditions, or with acute conditions. 
Finally, future research should gather evidence on feasibility and examine whether 
implementation of the GASI helps achieve patient-centered and systems-level goals in clinical 
practice. Initial evidence of feasibility is found in the current study as the GASI had fewer 
missing data than all other study measures. Future feasibility testing may include asking 
clinicians how long it took them to complete the GASI. Implementation research with the GASI 
would be suitable in a chronic care model.38 For example, because of the increasing use of 
patient satisfaction as a healthcare performance measure,195 pediatric outpatient practices using 
the chronic care model could investigate whether including the GASI within the clinical 
information system182 could support patient-provider discussion such that improvements are seen 
in child and parent (a) understanding of progress of the condition, (b) understanding of the care 
plan, and (c) satisfaction with the care plan.183 Such research would make a valuable contribution 
to the evidence for chronic care models, as robust evaluations are lacking.196 
With regards to implementation in clinical practice, discussions should begin surrounding 
the risks of using the GASI so that consequential validity56 can be established. Consequential 
validity is especially relevant in cases where a scale influences clinical decisions such as whether 
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or not a child meets program eligibility or should receive a certain medical intervention.12 
Physicians’ consensus at the Third Conference on Advances in Health Status Assessment was 
that measurement best informs practice when generic scales are used first and afterward 
supplemented by diagnosis- or problem-specific scales.197 Following such guidelines may reduce 
the risk of negative consequences of scale use. Additional considerations on how to interpret and 
respond to severity data have been previously published55 and also provided by generic scales 
such as the Global Assessment Scale (GAS)76 and Severity of Illness Score (SIS).110 Though 
some have argued that the consequences of using a subjective scale should be primarily 
attributed to the clinician,198,199 knowledgeable informants such as children and parents are also 
responsible for the outcomes of care in some ways.183 
Consequential validation should also consider how non-systematic use of a single-item 
global scale can result in variability of construct measurement, especially when the construct has 
previously been defined in different ways. Such measurement issues can be largely circumvented 
by paying careful attention to the question prompt of a scale. For example, numerous scales have 
been developed to measure both condition ‘control’ and condition 'severity.' With asthma, for 
instance, former definitions of severity provided by U.S. national asthma guidelines were 
narrow, defining severity as “the level of control in the unmedicated state.”88 This definition was 
irrelevant for the majority of asthma patients, only useful for initial consultations where asthma 
had not yet been treated. Addendums to this definition have since attempted to improve the 
usefulness of severity assessment,200 but the definition is still minimally relevant for the majority 
of outpatient visits. 
Fortunately, a definition of global severity is evident within the question prompt of the 
GASI and is relevant for routine clinical assessment of conditions like asthma. The question 
prompt of the GASI (see Figure 1) indicates that the severity rating should encompass all aspects 
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of a patient’s condition, not just a few, and not aspects less relevant to severity. Evidence that 
this occurs was demonstrated by discriminant validation in the current study. In fact, our findings 
showed that the GASI was significantly correlated with Treatability, the DUSOI item that is 
equivalent to condition control. Hence, in contrast to typically less relevant severity assessments 
of conditions like asthma, the GASI offers a useful severity assessment for the preponderance of 
clinical visits, including visits where condition control is an important component of the 
assessment. This study provides evidence that the severity definition of the GASI achieves what 
is recommended by Stein et al.,87 that each severity scale should be clear about its goal in 
measuring the severity construct. That said, careful attention to the question prompt will preserve 
utility of the GASI and minimize deviation in the construct that is measured. 
With these recommendations in mind, the GASI should be considered for a variety of 
activities in the clinical setting. For example, a clinician could use the GASI to track conditions 
over time by rating severity of a CPC at each visit and occasionally reviewing the trend of 
severity ratings. An increase in severity ratings could notify the clinician of the child’s 
deterioration and highlight the need to administer a more problem-specific assessment or 
reevaluate the child’s care plan. Similar action could also be taken if opportunities for 
improvement were available, but severity ratings remained unchanged over time. In contrast, if 
when reviewing GASI ratings the clinician notices a trend of decreasing severity or severity 
remaining stable at the level of “not at all severe,” they should consider whether additional 
changes in the child’s care plan (e.g., reducing pharmacotherapy) would improve the child’s 
quality of life without compromising stability of the CPC. 
Similar guidelines for scales have been followed in routine care for mental disorders9 and 
have been highly effective for complex systems-level healthcare coordination. For instance, 
according to a donor support coordinator at the Donor Network of Arizona (Tompke AA 2018, 
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email communication, 26th Nov), Arizona’s successful coordination of organ donation has relied 
heavily on systematic use of the Glasgow Coma Scale201 (GCS) for nearly 30 years. The GCS 
ranges from 3 (severe coma) to 15 (no impairment). The Donor Network of Arizona uses the 
GCS almost daily to (a) track ventilated patients with impaired consciousness and (b) facilitate 
communication between donor support coordinators, nurse practitioners, physicians, and organ 
procurement teams. If coordinators are notified of ventilated patients with an initial GCS score £ 
5, they immediately refer the patient for assessment with the organ recovery coordinator. 
However, if the GCS is above 5 they assign another team to track worsening or improvement of 
the condition over five days. Coordinators then make a follow-up phone call to the patient’s 
nurse and repeat this protocol.  
These GCS guidelines have demonstrated long-term success in supporting the work of 
numerous professionals coordinating health care across different settings. Elements of these 
guidelines could be translated for outpatient application of the GASI to improve systems-level 
activities, such as patient referrals. Resources for development and evaluation of clinical 
guidelines78,202 will make a valuable contribution to future explorations of the utility of the 
GASI. 
Conclusion 
 In conclusion, researchers and clinicians should be confident that rating severity using the 
GASI is valid and reliable when interpretation is limited to a dichotomous outcome of low or 
high severity. Initial evidence supports this approach when using the GASI among children with 
select chronic conditions in the outpatient setting. Additional research, ideally in a larger clinical 
sample, will be required to support interpretation of the full range of GASI ratings. The GASI 
can be used for monitoring severity over time and for making valid comparisons of severity 
between children with asthma, food allergy, diabetes, epilepsy, and juvenile arthritis. The GASI 
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presents numerous advantages over current scales that assess severity in children with chronic 
conditions and demonstrates potential to help reduce burdens on the healthcare system and 
improve the health of children.
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Appendix A 
Supplementary Psychometric Analysis 
(Assuming Ordinal/Nominal Outcomes) 
 
Table A1 – Concurrent Validity Assessed by AUC: Independent Associations 
  Baseline  6 Months  
Model Predictor Estimate SE p-Value n AUC Estimate SE p-Value n  AUC 
D. Symptoms 0.19 0.25 0.456 51 0.59 -0.27 0.26 0.304 51 0.58 
D. Complications 0.86 1.00 0.390 50 0.52 0.32 0.36 0.387 51 0.54 
D. Prognosis 1.53 0.44 <.001 53 0.90 1.37 0.39 <.001 51 0.88 
D. Treatability 2.47 1.12 0.028 52 0.66 13.95 191.40 0.942 51 0.77 
D. Composite 23.07 7.56 0.002 49 0.88 11.20 3.68 0.002 51 0.83 
VAS 41.21 97.22 0.672 52 0.99 2.53 0.79 0.001 51 0.88 
 
Area under the receiver operating characteristic curve (AUC) is reported. AUCs demonstrate strength of association between the GASI 
(dichotomized as Low/High severity) and individual DUSOI items, the DUSOI composite score, and the VAS. The GASI was dichotomized by 
aggregating ratings from “Not at all severe” to “A little severe” (Low severity) and “Somewhat severe” to “Extremely severe” (High severity). Bolded 




Table A2 – Concurrent Validity Assessed by AUC: Joint Model (GASI Outcome= Low/High Severity) 
  Baseline  6 Months  
Parameter Estimate SE p-Value Estimate SE p-Value 
Intercept -14.64 5.75 0.011 -28.59 384.6 0.006 
DUSOI Symptoms 1.15 0.59 0.049 -0.06 0.45 0.896 
DUSOI Complications 1.42 1.88 0.452 0.49 0.47 0.302 
DUSOI Prognosis 2.40 0.75 0.001 1.20 0.60 0.047 
DUSOI Treatability 3.20 1.98 0.106 12.81 192.3 0.004 
 Model: n= 49; AUC= 0.95 Model: n= 51; AUC= 0.93 
 
Area under the receiver operating characteristic curve (AUC) is reported. AUCs demonstrate strength of association between the GASI 
(dichotomized as Low/High severity) and the DUSOI, controlling for effects of each DUSOI item. GASI dichotomization is equivalent to Table 2. 










Table A3 – Concurrent Validity Assessed by AUC: Joint Model (GASI Outcome= No/Some Severity) 
  Baseline  6 Months  
Parameter Estimate SE p-Value Estimate SE p-Value 
Intercept -29.42 362.20 0.935 -9.26 6.52 0.155 
DUSOI Symptoms 1.49 0.68 0.027 0.09 0.56 0.878 
DUSOI Complications 11.92 343.3 0.972 1.00 1.00 0.315 
DUSOI Prognosis 1.81 0.58 0.002 2.94 1.07 0.006 
DUSOI Treatability 12.19 181.10 0.946 2.90 3.06 0.343 
 Model: n= 49; AUC= 0.93 Model: n= 51; AUC= 0.93 
 
Area under the receiver operating characteristic curve (AUC) is reported. AUCs demonstrate strength of association between the GASI 
(dichotomized as No/Some severity) and the DUSOI, controlling for effects of each DUSOI item. The GASI was dichotomized by distinguishing the 
rating “Not at all severe” (No severity) from ratings ranging from “A little severe” to “Extremely Severe” (Some severity). Bolded statistics come 









Table A4 – Sensitivity/Specificity Assessed by AUC: Single Predictor Per Model 
  GASI Sensitivity/Specificity (Maximum Likelihood Estimates)  
Measure Defining Stable vs. Changed Subgroup  Estimate SE p-Value n AUC 
DUSOI: Symptoms  0.12 0.20 0.540 47 0.56 
DUSOI: Complications  0.04 0.26 0.878 46 0.55 
DUSOI: Prognosis  0.27 0.21 0.205 49 0.67 
DUSOI: Treatability  -0.71 0.27 0.008 48 0.72 
DUSOI: Composite  -0.29 0.21 0.179 45 0.62 
VAS  -0.47 0.22 0.031 48 0.61 
 
Area under the receiver operating characteristic curve (AUC) is reported. AUCs demonstrate ability of the GASI to discriminate between Stable 
and Changed subgroups. Stable/Changed is defined by individual DUSOI items, the DUSOI composite score, and the VAS.  
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Appendix B 
Exploratory Data Analysis 
(Assuming Ordinal/Nominal Outcomes) 
 
 
Figure B1. Distribution of GASI ratings at baseline where x-axis represents all possible scale ratings and 
y-axis represents percent of children in the sample. 
 
 
Figure B2. Distribution of GASI ratings at six months where x-axis represents all possible scale ratings 
and y-axis represents percent of children in the sample. 
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Table B1 – Exploring Clinician Characteristics as Potential Confounders Using Fisher’s Exact Test 
Frequency Table 
 Baseline  6 Months 
Table Probability (P) p-Value n Table Probability (P) p-Value n 
Rater Confidence (Low/High) x 
ClinType (Imm, End, Neur, Rheu) 
0.003 0.095 53 <.001 0.004 50 
 
The results of Fisher’s Exact test are reported for the frequency table with the row/column variables rater confidence (dichotomized as Low/High) 
and type of clinical specialist measuring severity (four types).  
Rater confidence= the confidence that clinicians reported having in their severity assessment upon completing the clinician form (i.e., one 
confidence rating pertains to all three severity scales) 












Table B2 – Exploring Validity with Clinician Characteristics as Covariate Using the AUC 
  Baseline  6 Months  
Parameter Estimate SE p-Value Estimate SE p-Value 
Intercept -9.40 3.09 0.002 -5.55 1.80 0.002 
DUSOI Composite 25.40 8.62 0.003 12.19 4.03 0.003 
ClinType -0.32 0.36 0.371 0.31 0.28 0.278 
 Model: n= 48; AUC= 0.90 Model: n= 50; AUC= 0.83 
 
Area under the receiver operating characteristic curve (AUC) is reported. AUCs demonstrate strength of association between the GASI 
(dependent variable; dichotomized as Low/High severity) and the DUSOI Composite score (independent variable) where the clinician 
characteristic “ClinType” is a covariate. GASI dichotomization is equivalent to Table 2. 











Table B3 – Exploring Validity with Clinician Characteristics as Covariate Using the AUC 
  Baseline  6 Months  
Parameter Estimate SE p-Value Estimate SE p-Value 
Intercept -8.69 3.14 0.006 -2.94 2.28 0.197 
DUSOI Composite 23.29 7.70 0.003 9.72 3.75 0.010 
Rater Confidence -0.29 0.94 0.755 -0.64 0.80 0.426 
 Model: n= 48; AUC= 0.89 Model: n= 50; AUC= 0.82 
 
Area under the receiver operating characteristic curve (AUC) is reported. AUCs demonstrate strength of association between the GASI 
(dependent variable; dichotomized as Low/High severity) and the DUSOI Composite score (independent variable) where the clinician 
characteristic “Rater Confidence” is a covariate. GASI dichotomization is equivalent to Table 2. 
 
Table B4 – Exploring Relationships Between Sample Characteristics and GASI Ratings 
Test  Baseline  6 Months  
Fisher’s Exact Test (GASI x Diagnosis) Table Probability: <.001 p-Value: 0.005 Table Probability: <.001 p-Value: <.001 
Fisher’s Exact Test (GASI x Sex) Table Probability: 0.004 p-Value: 0.495 Table Probability: <.001 p-Value: 0.202 
Kendall’s tc Correlation (GASI x Age) Coefficient (tc): 0.09 p-Value: 0.445 Coefficient (tc): -0.08 p-Value: 0.535 
 




Alternative Psychometric Analysis 
(Assuming Continuous Outcomes) 
 
Table C1 – Concurrent Validity Assessed by Spearman-Rank Correlation 
  Baseline  6 Months 
Severity Measure r (95% CI) p-Value n r (95% CI) p-Value n 
DUSOI: Symptoms 0.28 (0.00, 0.51) 0.047 51 -0.09 (-0.35, 0.20) 0.550 51 
DUSOI: Complications 0.15 (-0.13, 0.41) 0.295 50 0.11 (-0.17, 0.37) 0.446 51 
DUSOI: Prognosis 0.74 (0.58, 0.84) <.001 53 0.82 (0.69, 0.89) <.001 51 
DUSOI: Treatability 0.41 (0.15, 0.61) 0.002 52 0.63 (0.42, 0.77) <.001 51 
DUSOI: Composite 0.76 (0.61, 0.86) <.001 49 0.72 (0.55, 0.83) <.001 51 
VAS 0.87 (0.78, 0.92) <.001 52 0.86 (0.76, 0.91) <.001 51 
 
Spearman-Rank correlation coefficients (rho) are reported with 95% confidence intervals at baseline and 6 months for correlation of the GASI with 






Table C2 – Concurrent Validity Assessed by Multiple Linear Regression: Joint Model 
 Baseline  6 Months  
Parameter Estimate SE p-Value 95% CI  Estimate SE p-Value 95% CI 
Intercept -0.67 0.45 0.14 (-1.58, 0.24)  -1.37 0.56 0.02 (-2.49, -0.24) 
D. Symptoms 0.24 0.11 0.03 (0.02, 0.46)  -0.06 0.11 0.57 (-0.28, 0.16) 
D. Complications 0.53 0.40 0.19 (-.28, 1.33)  0.48 0.15 <.01 (0.18, 0.78) 
D. Prognosis 0.64 0.10 <.01 (0.44, 0.84)  0.67 0.10 <.01 (0.47, 0.86) 
D. Treatability 0.20 0.23 0.38 (-.26, 0.67)  0.86 0.26 <.01 (0.33, 1.39) 
 Model: n= 49; Adjusted R2= 0.53 Model: n= 51; Adjusted R2= 0.78 
 
Multiple linear regression coefficients are reported where all DUSOI items are included in the model. R2 indicates amount of variation in the GASI 
that can be explained by variation in the DUSOI. 
D.= DUSOI 









Table C3 – Concurrent Validity Assessed by Multiple Linear Regression: Model Includes DUSOI Composite Score 
 Baseline  6 Months  
Parameter Estimate SE p-Value 95% CI  Estimate SE p-Value 95% CI 
Intercept -1.02 0.37 <.01 (-1.76, -0.29)  -1.15 0.56 0.04 (-2.27, -0.03) 
DUSOI Composite 6.79 1.06 <.01 (4.67, 8.91)  7.93 1.56 <.01 (4.80, 11.06) 
 Model: n= 49; R2= 0.47 Model: n= 51; R2= 0.35 
 
Multiple linear regression coefficients are reported. R2 indicates amount of variation in the GASI that can be explained by variation in the DUSOI 
Composite score. 
SE= Standard error 
 
Table C4 – Concurrent Validity Assessed by Multiple Linear Regression: Model Includes VAS 
 Baseline  6 Months  
Parameter Estimate SE p-Value 95% CI  Estimate SE p-Value 95% CI 
Intercept 0.04 0.10 0.72 (-.17, 0.24)  -0.30 0.13 0.03 (-0.57, -0.03) 
VAS 0.95 0.06 <.01 (0.84, 1.07)  1.14 0.06 <.01 (1.01, 1.26) 
 Model: n= 52; R2= 0.84 Model: n= 51; R2= 0.87 
 
Multiple linear regression coefficients are reported. R2 indicates amount of variation in the GASI that can be explained by variation in the VAS. 
SE= Standard error 
 
 89 
Table C5 – Discriminant Validity Assessed by Spearman-Rank Correlation 
KIDSCREEN-27 Domain 
 Baseline  6 Months 
r (95% CI) p-Value n r (95% CI) p-Value n 
Physical Well-being -0.02 (-0.30, 0.26) 0.878 48 0.11 (-0.20, 0.39) 0.486 44 
Psychological Well-being -0.09 (-0.36, 0.20) 0.543 49 -0.07 (-0.36, 0.23) 0.649 43 
Parents and Autonomy -0.003 (-0.29, 0.28) 0.983 48 0.07 (-0.24, 0.36) 0.667 44 
Social Support and Peers -0.12 (-0.39, 0.16) 0.396 49 -0.10 (-0.39, 0.20) 0.507 44 
School Environment -0.09 (-0.37, 0.20) 0.538 46 -0.13 (-0.42, 0.17) 0.392 43 
 
Spearman-Rank correlation coefficients (rho) are reported with 95% confidence intervals at baseline and 6 months for correlation of the GASI with 




Table C6 – Discriminative Validity Assessed by Mann-Whitney U Test (Wilcoxon Rank Sum Test) 
 
Severity Subgroups 
 Baseline  6 Months 
Test Statistic p-Value n Test Statistic p-Value n 
Multimorbidity vs.  
No Multimorbidity 
563 0.151 55 557 0.833 51 
 
Test statistics for the Mann-Whitney U Test are reported. 
 
Table C7 – Test-retest Reliability Assessed by Wilcoxon Signed-Rank Test 
Measure Defining Stable Subgroup Test Statistic (S) p-Value n 
DUSOI: Symptoms -28 0.046 27 
DUSOI: Complications -29.5 0.204 38 
DUSOI: Prognosis -25.5 0.052 30 
DUSOI: Treatability 16.5 0.400 34 
DUSOI: Composite -2.5 0.905 29 
VAS 10 0.234 28 
 













Table C8 – Test-retest Reliability Assessed by Intraclass Correlation Coefficient 
Measure Defining Stable Subgroup ICC (95% CI) n 
DUSOI: Symptoms 0.60 (0.52, 0.68) 27 
DUSOI: Complications 0.53 (0.45, 0.69) 38 
DUSOI: Prognosis 0.61 (0.50, 0.74) 30 
DUSOI: Treatability 0.44 (0.21, 0.51) 34 
DUSOI: Composite 0.52 (0.34, 0.76) 29 
VAS 0.87 (0.65, 0.95) 28 
 
Bootstrapped intraclass correlation coefficients [ICC (A, 1)] with 95% confidence intervals (CI) are 
reported. Coefficients were computed using GASI ratings from children in the Stable subgroup. Stable is 
defined by individual DUSOI items, the DUSOI composite score, and the VAS. Bootstrapped ICCs were 
calculated using a 2-way mixed effects model requiring absolute agreement because clinicians rated 
condition severity in the same patients170,203 at baseline and at 6 months. It should be noted that this ICC 
is computationally equivalent to the random effects ICC [ICC (2,1)],170 but is not termed “random” in this 
context because inter-rater reliability is not being formally tested (i.e., children were not randomized to 
different clinicians). 
